Trial Profile
A multi-center, observational, cohort study investigating the efficacy and safety of sofosbuvir and ribavirin in patients with hepatitis C virus in German hepatitis C-registry in real-world setting
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2017
Price :
$35
*
At a glance
- Drugs Sofosbuvir (Primary) ; Daclatasvir; Ledipasvir/sofosbuvir; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 13 May 2016 New trial record
- 17 Apr 2016 Results of patients with HCV genotype 2 infection (n=194) presented at The International Liver Congress™ 2016
- 17 Apr 2016 Subgroup analysis (n=706) of SVR rates of ledipasvir/sofosbuvir treatment for 8-12 weeks until September 2015, in hepatitis C genotype 1 treatment-naive patients were presented at The International Liver Congress™ 2016.